Sahlgrenska Academy / Sahlgrenska akademin >
Institute of Clinical Sciences / Institutionen för kliniska vetenskaper >
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper >

Evaluation of regulator of G-protein signaling 2 (RGS2) at different stages of prostate cancer - Significance and clinical potential

Please use this identifier to cite or link to this item:

Files in This Item:

File Description SizeFormat
gupea_2077_59541_1.pdfThesis frame1279KbAdobe PDF
gupea_2077_59541_2.pdfAbstract235KbAdobe PDF
Title: Evaluation of regulator of G-protein signaling 2 (RGS2) at different stages of prostate cancer - Significance and clinical potential
Authors: Linder, Anna
Issue Date: 15-May-2019
University: University of Gothenburg. Sahlgrenska Academy
Institution: Institute of Clinical Sciences. Department of Urology
Parts of work: I. Linder A, Hagberg Thulin M, Damber JE, Welén K. Analysis of regulator of G-protein signalling 2 (RGS2) expression and function during prostate cancer progression. Scientific reports. 2018; 8: 1-14

II. Linder A, Larsson K, Welén K, Damber JE, RGS2 is prognostic for development of castration-resistance and cancer-specific survival in CRPC. Manuscript

III. Linder A, Spyratou V, Larsson K, Stattin P, Granfors T, Egevad L, Linxweiler J, Jung V, Junker K, Saar M, Hammarsten P, Bergh A, Welén K, Damber JE, Josefsson A. Prognostic value of stromal expression of regulator of G protein signaling 2 (RGS2) and androgen receptor (AR) for men with prostate cancer followed with expectancy management. Manuscript

IV. Linder A, Hagberg Thulin M, Welén K, Damber JE. Importance of RGS2 in prostate cancer bone metastases. Manuscript
Date of Defence: 2019-06-05
Disputation: Onsdagen den 5 juni, kl 9.00, Hörsal Ragnar Sandberg, Medicinaregatan 7A, Göteborg
Degree: Doctor of Philosophy (Medicine)
Publication type: Doctoral thesis
Keywords: Prostate cancer
Regulator of G-protein signaling 2 (RGS2)
Androgen receptor
Prostate cancer bone metastases
Abstract: Prostate cancer (PC) is often a slow-growing and symptom-free disease with good prognosis. However, a substantial number will progress, ultimately metastasize if left untreated and finally kill the patient. The standard treatment for these stages of PC is androgen deprivation therapy (ADT), which generally has an initially good clinical response. However, ADT drives development of highly aggressive forms of castration-resistant PC (CRPC) and promote development of bone metastases. Thus, ear... more
ISBN: 978-91-7833-470-4 (PRINT)
978-91-7833-471-1 (PDF)
Appears in Collections:Doctoral Theses from Sahlgrenska Academy
Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper



© Göteborgs universitet 2011